Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

ConclusionsTET1-MUT was strongly associated with higher ORR, better DCB, longer PFS, and improved OS in patients receiving ICI treatment, suggesting thatTET1-MUT is a novel predictive biomarker for immune checkpoint blockade across multiple cancer types.

http://link.springer.com/10.1186/s40425-019-0737-3

Source: Journal for Immunotherapy of Cancer - October 16, 2019 Category: Cancer & Oncology Source Type: research